IperionX shares gave back 8.3% yesterday, snapping a three-day run that had been built on the September-quarter report rather than any fresh company announcement. Media coverage pointed to profit-taking and a softer backdrop for Australian resources and defense-adjacent technology names as the likely culprits. The pullback says little about the operational story underneath — and that story, on closer reading, is less about the next Army contract than about whether the company’s technology can scale.
Output and capacity are two different numbers
For the September quarter of 2026, IperionX reported titanium powder production of 8.7 tonnes, up from 1.4 tonnes in the June quarter. The validated annualized capacity of its HAMR furnace also cleared the 200-tonne target the company had set for itself.
The distinction matters. Quarterly output describes what was actually produced; validated annual capacity describes the performance level the plant demonstrated during validation. Treating the two as interchangeable turns a technical milestone into an economic one prematurely. The powder itself met or exceeded the Grade 5 titanium standard — so the report speaks to quality as well as volume, though high-grade material alone does not make a scalable business while production remains too costly.
Where the real leverage sits
Against the batch-wise HAMR system, IperionX’s continuous GenX process delivered six times the throughput over the same run time. Electricity consumption per kilogram of titanium powder fell by more than 75%. Magnesium and hydrogen requirements dropped markedly as well, and every valid sample met ASTM oxygen-content requirements.
Those savings target exactly the point where industrial scaling has to prove itself — but no concrete margin can be derived from them yet. The same yardstick applies more broadly: Reuters reported today that rising AI spending is weighing on share buybacks at large technology companies, leaving investors more dependent on those investments eventually delivering earnings growth. IperionX is no AI hyperscaler, but the valuation logic overlaps — technical capability has to show up in financial results at some point.
Reading the Army order correctly
Separately, IperionX disclosed a second task order from the U.S. Army with a base value of US$18.5 million, of which US$11.5 million is initially funded. Including options, the potential value can reach US$25.4 million. Base value, initial funding commitment and options are not interchangeable figures, and the maximum volume is not a fully secured cash inflow.
Should investors sell immediately? Or is it worth buying IperionX?
The order does add a concrete customer reference to the technical progress. IperionX also reported a follow-on order from the U.S. Army Ground Vehicle Systems Center for titanium fasteners destined for the Joint Light Tactical Vehicle and its associated trailer. According to the company, the components beat the torque yield-strength performance of SAE Grade 8 steel fasteners in independent testing.
Liquidity frames the runway
At quarter-end, IperionX held US$63 million in cash, supplemented by US$33.7 million in reimbursable government funds. The company put available liquidity at roughly US$96.7 million. Here too, the split between cash on hand and additionally available funds is worth keeping in view: liquidity provides the financial room to execute, but it does not substitute for proof of economic production.
Investors will get a chance to press management on that gap. IperionX has scheduled an investor webinar with CEO Taso Arima for 3 November 2026, starting at 10:00 a.m. Australian Eastern Daylight Time — 2 November 2026 at 6:00 p.m. for listeners on the U.S. East Coast.
The measure that matters is neither the latest order nor the largest capacity figure. It is whether IperionX can permanently combine higher volumes, dependable quality and lower resource intensity. The quarterly report shows progress on that path — and its value to investors lies precisely in making the industrial test more concrete, and therefore easier to check.
Ad
IperionX Stock: Buy or Sell?! New IperionX Analysis from October 31 delivers the answer:
The latest IperionX figures speak for themselves: Urgent action needed for IperionX investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 31.
IperionX: Buy or sell? Read more here...
